These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 1280705)

  • 1. Renal effects of alacepril in essential hypertension.
    Tomita K; Nonoguchi H; Terada Y; Marumo F
    J Cardiovasc Pharmacol; 1992 Oct; 20(4):520-4. PubMed ID: 1280705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of the novel orally active angiotensin converting enzyme inhibitor alacepril on cardiovascular system in experimental animals.
    Takeyama K; Minato H; Nakatsuji K; Suzuki H; Nose I; Oka M; Hosoki K; Hatano N; Kadokawa T
    Arzneimittelforschung; 1986; 36(1):69-73. PubMed ID: 3513779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Racial differences in the renal response to blood pressure lowering during chronic angiotensin-converting enzyme inhibition: a prospective double-blind randomized comparison of fosinopril and lisinopril in older hypertensive patients with chronic renal insufficiency.
    Mitchell HC; Smith RD; Cutler RE; Sica D; Videen J; Thompsen-Bell S; Jones K; Bradley-Guidry C; Toto RD
    Am J Kidney Dis; 1997 Jun; 29(6):897-906. PubMed ID: 9186076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term plasma levels and dose modulation of alacepril in patients with chronic renal failure.
    Nonoguchi H; Kiyama S; Kitamura K; Naruse M; Tomita M; Tazoe N; Tajiri M; Nakayama Y; Kohda Y; Inoue T; Tomita K
    Hypertens Res; 2008 Jan; 31(1):29-36. PubMed ID: 18360015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanistic analysis of renal protection by angiotensin converting enzyme inhibitor in Dahl salt-sensitive rats.
    Hirawa N; Uehara Y; Kawabata Y; Ohshima N; Ono H; Nagata T; Gomi T; Ikeda T; Goto A; Yagi S
    J Hypertens; 1994 Aug; 12(8):909-18. PubMed ID: 7814850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of an angiotensin-converting enzyme inhibitor, alacepril, on cardiovascular and sympathetic nervous responses to mental stress in patients with essential hypertension.
    Saitoh M; Miyakoda H; Kitamura H; Kinugawa T; Kotake H; Mashiba H
    Intern Med; 1993 Sep; 32(9):691-4. PubMed ID: 8142672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the effect of an angiotensin-converting enzyme inhibitor, alacepril, on drug-induced renin-angiotensin-aldosterone system activation in normal dogs.
    Sakatani A; Miyagawa Y; Takemura N
    J Vet Cardiol; 2016 Sep; 18(3):248-254. PubMed ID: 27364087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of alacepril on 24-hour blood pressure in elderly hypertensive patients.
    Kohara K; Hara-Nakamura N; Takada Y; Iwata T; Ochi T; Kukita H; Muneta S; Hiwada K
    Int J Clin Pharmacol Ther; 1996 Sep; 34(9):380-3. PubMed ID: 8880286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of alpha-adrenergic blockers, ACE inhibitors, and calcium channel antagonists on renal function in hypertensive non-insulin-dependent diabetic patients.
    Giordano M; Sanders LR; Castellino P; Canessa ML; DeFronzo RA
    Nephron; 1996; 72(3):447-53. PubMed ID: 8852495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of a long-term treatment with alacepril on left ventricular hypertrophy and function in patients with essential hypertension.
    Sumimoto T; Ochi T; Hiwada K
    J Clin Pharmacol; 1992 Jul; 32(7):667-70. PubMed ID: 1386375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. General pharmacology of the novel angiotensin converting enzyme inhibitor alacepril. 1st communication: Effects on cardiovascular, visceral and renal functions and on blood.
    Matsuno Y; Taira N; Fujitani B; Ito T; Kadokawa T
    Arzneimittelforschung; 1986; 36(1):55-62. PubMed ID: 3513777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of antihypertensive treatment with alacepril on insulin resistance in diabetic spontaneously hypertensive rats.
    Sato T; Nara Y; Kato Y; Yamori Y
    Metabolism; 1996 Apr; 45(4):457-62. PubMed ID: 8609831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tissue levels, tissue angiotensin converting enzyme inhibition and antihypertensive effect of the novel antihypertensive agent alacepril in renal hypertensive rats.
    Nambu K; Matsumoto K; Takeyama K; Hosoki K; Miyazaki H; Hashimoto M
    Arzneimittelforschung; 1986; 36(1):47-51. PubMed ID: 3006710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antihypertensive activity of alacepril, an orally active angiotensin converting enzyme inhibitor, in renal hypertensive rats and dogs.
    Takeyama K; Minato H; Fukuya F; Kawahara S; Hosoki K; Kadokawa T
    Arzneimittelforschung; 1985; 35(10):1502-7. PubMed ID: 3000389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of alacepril and amlodipine on the renal injury induced by a high-cholesterol diet in rats.
    Atarashi K; Takagi M; Minami M; Ishiyama A
    J Hypertens; 1999 Dec; 17(12 Pt 2):1983-6. PubMed ID: 10703899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antihypertensive activity of alacepril in spontaneously hypertensive rats and deoxycorticosterone acetate-salt hypertensive rats and dogs.
    Takeyama K; Minato H; Fukuya F; Kawahara S; Hosoki K; Kadokawa T
    Arzneimittelforschung; 1985; 35(10):1507-12. PubMed ID: 3000390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute effects of the new oral angiotensin converting enzyme inhibitor 1-(D-3-acetylthio-2-methylpropanoyl)-L-prolyl-L-phenylalanine (Alacepril) in essential hypertension.
    Mizuno K; Hashimoto S; Kunii N; Tani M; Niimura S; Yabe R; Watari H; Fukuchi S
    Res Commun Chem Pathol Pharmacol; 1985 Aug; 49(2):175-87. PubMed ID: 2997886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of angiotensin-converting enzyme inhibition on altered renal hemodynamics induced by low protein diet in the rat.
    Fernández-Repollet E; Tapia E; Martínez-Maldonado M
    J Clin Invest; 1987 Oct; 80(4):1045-9. PubMed ID: 3308957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of the angiotensin converting enzyme inhibitors captopril, rentiapril, and alacepril in patients with essential and renovascular hypertension.
    Ideishi M; Sasaguri M; Ikeda M; Arakawa K
    Clin Ther; 1989; 11(4):441-51. PubMed ID: 2550133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of alacepril on blood pressure and neurohumoral factors at rest and during dynamic exercise in patients with essential hypertension.
    Kinugawa T; Kitamura H; Ogino K; Noguchi N; Matsumoto T; Hisatome I; Miyakoda H; Kotake H; Mashiba H
    Br J Clin Pharmacol; 1992 Oct; 34(4):366-9. PubMed ID: 1457272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.